A novel flow cytometric assay for detection of residual disease in patients with B‐lymphoblastic leukemia/lymphoma post anti‐CD19 therapy

Publisher： John Wiley & Sons Inc

E-ISSN： 1552-4957|94|1|112-120

ISSN： 1552-4949

Source： Cytometry. Part B: Clinical Cytometry, Vol.94, Iss.1, 2018-01, pp. : 112-120

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Detection of minimal residual disease in B lymphoblastic leukemia using viSNE

By  

Cytometry. Part B: Clinical Cytometry, Vol. 88, Iss. 5, 2015-09 ,pp. : 294-304

John Wiley & Sons Inc

Access to resources Recommend Favorite

Implementation of a simplified flow cytometric assays for minimal residual disease monitoring in childhood acute lymphoblastic leukemia

By  

Cytometry. Part B: Clinical Cytometry, Vol. 94, Iss. 1, 2018-01 ,pp. : 94-99

John Wiley & Sons Inc

Access to resources Recommend Favorite

Evaluation of new markers for minimal residual disease monitoring in B‐cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; 00B: 000–000

By  

Cytometry. Part B: Clinical Cytometry, Vol. 94, Iss. 1, 2018-01 ,pp. : 100-111

John Wiley & Sons Inc

Access to resources Recommend Favorite

Simultaneous use of multiplex ligation‐dependent probe amplification assay and flow cytometric DNA ploidy analysis in patients with acute leukemia

By  

Cytometry. Part B: Clinical Cytometry, Vol. 94, Iss. 1, 2018-01 ,pp. : 172-181

John Wiley & Sons Inc

Access to resources Recommend Favorite

CD49d shows superior performance characteristics for flow cytometric prognostic testing in chronic lymphocytic leukemia/small lymphocytic lymphoma

By  

Cytometry. Part B: Clinical Cytometry, Vol. 94, Iss. 1, 2018-01 ,pp. : 129-135

John Wiley & Sons Inc

Access to resources Recommend Favorite